Waystar Holding (WAY) has drawn fresh attention after publishing The State of the Mid-Revenue Cycle report, which spotlights healthcare finance leaders’ push for a single AI-powered platform that links mid-cycle workflows with final claims processing.

Despite the spotlight from its new mid-revenue cycle report, Waystar Holding’s short term momentum has been weak. The share price is down 10.34% over 30 days and 38.89% year to date, while the 1 year total shareholder return has declined 52.82%.

If this AI push in healthcare has caught your eye, it could be worth broadening your watchlist with other healthcare AI opportunities using the 39 healthcare AI stocks

With the stock down sharply over the past year, yet trading at a reported 54% discount to one intrinsic value estimate and 76% below the average analyst target, is this a mispriced healthcare AI platform, or is the market already discounting future growth?

Most Popular Narrative: 43.3% Undervalued

Compared with the last close at $19.17, the most followed narrative pegs Waystar Holding’s fair value near $33.83, using an 8.93% discount rate as a key input.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth. Providers facing increasing administrative complexity, demand for interoperability, and shifting payer dynamics are prioritizing adoption of robust, cloud-based RCM software like Waystar's, which has demonstrated superior automation and ROI for clients, supporting both strong new client wins and high net revenue retention, likely driving sustained double-digit topline growth.

Curious what has to happen for that higher fair value to stack up? The narrative leans on faster earnings expansion, firmer margins and a richer future earnings multiple. The exact mix of growth, profitability and valuation expectations might surprise you.

Result: Fair Value of $33.83 (UNDERVALUED)

However, there is still real execution risk. Higher leverage from the US$1.25b Iodine deal and rapid AI competition could both derail the upbeat earnings narrative.

Next Steps

Given the mix of weak recent returns and a bullish narrative, it makes sense to move quickly and check the numbers yourself rather than rely on headlines alone. To see what investors are optimistic about, review the 4 key rewards.

Looking for more investment ideas?

If Waystar has your attention, do not stop here. Broaden your watchlist with other data driven ideas that could suit very different goals and risk levels.

• Target potential value opportunities by scanning companies that screen as 46 high quality undervalued stocks.
• Prioritize stability and capital protection by reviewing 63 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with strong fundamentals through the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.